Kristin M. Tiemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristin M. Tiemann has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- David A. Hunstad
Department of Pediatrics, Washington University School of Medicine
2 shared publications - Lisa K. McLellan
Department of Biological Sciences, College of Science, Purdue University Fort Wayne
2 shared publications Alice Liu
Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA
1 shared publication- Alice Q. Liu
Division of Otolaryngology - Head and Neck Surgery, University of British Columbia, Vancouver, Canada
1 shared publication Allyssa L. Daugherty
Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA
1 shared publication- Allyssa L. Daugherty
Department of Neurology, Washington University School of Medicine in St. Louis
1 shared publication
Latest Publications
- Open Access
- 1 September 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9)
Correction: Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis (doi: 10.1242/dmm.030130)
There was an error published in Dis. Model. Mech. 10, 1371-1379 (doi: 10.1242/dmm.030130).
- 1 September 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9)
Open AccessCorrection: Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis (doi: 10.1242/dmm.030130)
There was an error published in Dis. Model. Mech. 10, 1371-1379 (doi: 10.1242/dmm.030130).
- Open Access
- 1 January 2017
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 10 (11) , 1371-1379
Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis
We present a new preclinical model to study treatment, resolution and sequelae of severe ascending pyelonephritis. Urinary tract infection (UTI), primarily caused by uropathogenic Escherichia coli (UPEC), is a common disease in children. Severe pyelonephritis is the primary cause of acquired renal scarring in childhood, which may eventually lead to hypertension and chronic kidney disease in a small but important fraction of patients. Preclinical modeling of UTI utilizes almost exclusively females, which (in most mouse strains) exhibit inherent resistance to severe ascending kidney infection; consequently, no existing preclinical model has assessed the consequences of recovery from pyelonephritis following antibiotic treatment. We recently published a novel mini-surgical bladder inoculation technique, with which male C3H/HeN mice develop robust ascending pyelonephritis, highly prevalent renal abscesses and evidence of fibrosis. Here, we devised and optimized an antibiotic treatment strategy within this male model to more closely reflect the clinical course of pyelonephritis. A 5-day ceftriaxone regimen initiated at the onset of abscess development achieved resolution of bladder and kidney infection. A minority of treated mice displayed persistent histological abscess at the end of treatment, despite microbiological cure of pyelonephritis; a matching fraction of mice 1 month later exhibited renal scars featuring fibrosis and ongoing inflammatory infiltrates. Successful antibiotic treatment preserved renal function in almost all infected mice, as assessed by biochemical markers 1 and 5 months post-treatment; hydronephrosis was observed as a late effect of treated pyelonephritis. An occasional mouse developed chronic kidney disease, generally reflecting the incidence of this late sequela in humans. In total, this model offers a platform to study the molecular pathogenesis of pyelonephritis, response to antibiotic therapy and emergence of sequelae, including fibrosis and renal scarring. Future studies in this system may inform adjunctive therapies that may reduce the long-term complications of this very common bacterial infection.
- 1 January 2017
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 10 (11) , 1371-1379
Open AccessRenal scar formation and kidney function following antibiotic-treated murine pyelonephritis
We present a new preclinical model to study treatment, resolution and sequelae of severe ascending pyelonephritis. Urinary tract infection (UTI), primarily caused by uropathogenic Escherichia coli (UPEC), is a common disease in children. Severe pyelonephritis is the primary cause of acquired renal scarring in childhood, which may eventually lead to hypertension and chronic kidney disease in a small but important fraction of patients. Preclinical modeling of UTI utilizes almost exclusively females, which (in most mouse strains) exhibit inherent resistance to severe ascending kidney infection; consequently, no existing preclinical model has assessed the consequences of recovery from pyelonephritis following antibiotic treatment. We recently published a novel mini-surgical bladder inoculation technique, with which male C3H/HeN mice develop robust ascending pyelonephritis, highly prevalent renal abscesses and evidence of fibrosis. Here, we devised and optimized an antibiotic treatment strategy within this male model to more closely reflect the clinical course of pyelonephritis. A 5-day ceftriaxone regimen initiated at the onset of abscess development achieved resolution of bladder and kidney infection. A minority of treated mice displayed persistent histological abscess at the end of treatment, despite microbiological cure of pyelonephritis; a matching fraction of mice 1 month later exhibited renal scars featuring fibrosis and ongoing inflammatory infiltrates. Successful antibiotic treatment preserved renal function in almost all infected mice, as assessed by biochemical markers 1 and 5 months post-treatment; hydronephrosis was observed as a late effect of treated pyelonephritis. An occasional mouse developed chronic kidney disease, generally reflecting the incidence of this late sequela in humans. In total, this model offers a platform to study the molecular pathogenesis of pyelonephritis, response to antibiotic therapy and emergence of sequelae, including fibrosis and renal scarring. Future studies in this system may inform adjunctive therapies that may reduce the long-term complications of this very common bacterial infection.